// App-Quantinova.ai

495 : Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis

Researchers

Presenter

  • Juliana Craig

Principal Investigators

  • Maria Iglesias

  • Kristen Cunanan

  • Sally Arai

  • Matthew J. Frank

  • Laura J. Johnston

  • Robert Lowsky

  • Everett H Meyer

  • David B. Miklos

  • Robert S. Negrin

  • Andrew R. Rezvani

  • Judith A Shizuru

  • Surbhi Sidana

  • W-K Weng

  • Parveen Shiraz

  • Lori Muffly

Medical Centers

  • Stanford School of Medicine, Stanford, CA

  • Stanford Medicine Quantitative Sciences, Palo Alto, CA

  • Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA

  • Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA

  • Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

  • Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Estrogen receptor alpha

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved